Yang, Hua
Tan, Shanshan http://orcid.org/0000-0002-4303-3916
Qiao, Jingjuan http://orcid.org/0000-0002-4277-6531
Xu, Yiting
Gui, Zongxiang
Meng, Yuguang http://orcid.org/0000-0002-6734-8779
Dong, Bin
Peng, Guangda
Ibhagui, Oluwatosin Y.
Qian, Weiping
Lu, Jimmy
Li, Zezhong
Wang, Guimin
Lai, Jinping
Yang, Lily
Grossniklaus, Hans E. http://orcid.org/0000-0003-0178-9712
Yang, Jenny J. http://orcid.org/0000-0002-2310-7658
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R33CA235319, R42CA183376)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Eye Institute (P3006360)
Article History
Received: 17 August 2021
Revised: 12 December 2021
Accepted: 26 January 2022
First Online: 10 February 2022
Competing interests
: JJY holds shares in the company InLighta Biosciences LLC, which licenses the rights to commercialize ProCAs. JL holds shares in the company Codex Biosolution. JJY is a named inventor on issued or pending patents (US8173105 (EP1901659), US8367040 (EP3378496) contrast agents), (US9339559 (EP1928507, CA 2621763), US 10525150 targeted contrast agents), (US9956304 (EP2257316), US15/910893, US17/068215 contrast agents and imaging), (US15/572,863 (WO16793465.2) targeted contrast agents). The remaining authors declare no competing interests.